Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals Inc (NQ: CRNX )

50.58 +0.13 (+0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 676,339
Open 50.97
Bid (Size) 35.02 (1)
Ask (Size) 52.00 (41)
Prev. Close 50.45
Today's Range 50.28 - 51.81
52wk Range 25.35 - 55.78
Shares Outstanding 54,026,103
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+42.92%
+42.92%
1 Month
-7.14%
-7.14%
3 Month
+16.36%
+16.36%
6 Month
+8.05%
+8.05%
1 Year
+80.45%
+80.45%

More News

Read More
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals
Via Benzinga
Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals
Via Benzinga
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
17 Analysts Have This To Say About Crinetics Pharmaceuticals
Via Benzinga
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
18 Analysts Have This To Say About Crinetics Pharmaceuticals
Via Benzinga
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Via InvestorPlace
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.